Nasdaq Stock Winners: VERU, HOTH, KTRA
3:50 pm Monday, April 11th, 2022
Veru Inc (NASDAQ:VERU) stock is taking off on Monday as investors react to recent news about the company’s Covid-19 treatment. The big news here is the mortality rate of Covid-19 patients treated with sabizabulin as compared to those in a placebo group. The Phase 3 clinical trial reported a 20% mortality rate for those taking sabizabulin, as compared to a 45% mortality rate for those in the placebo group. In addition to this, Veru reported that sabizabulin 9 mg was well tolerated during the Phase 3 clinical trial. That includes no clinically relevant safety observations in the treatment group compared to the placebo group.
Hoth Therapeutics Inc (NASDAQ:HOTH) stock is rising higher on Monday after the biopharmaceutical company provided an update on HT-KIT. HT-KIT is the company’s novel cancer therapeutic still in development. The positive news sending the stock higher today comes from recent results from the drug. That includes effectiveness in the treatment of cancer. According to this data, HT-KIT was successful in reducing KIT protein expression, signaling, and function in leukemia cells in vitro. It also prevented further cell growth, as well as induced cell death over 72 hours.
Kintara Therapeutics Inc (NASDAQ:KTRA) today announces that it has presented data at the 2022 American Association for Cancer Research (AACR) Annual Meeting. Enhanced drug concentrations of VAL-083 in the brain and GBM brain tumors in comparison to circulating plasma concentrations have been observed in human clinical trials. Most therapeutic agents targeting brain tumors have very limited access to primary brain tumors due to the protective nature of the BBB that limits access for most chemical structures.
